The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of ...

The new partnership between DexCom and Google to build out a new class of continuous glucose monitors spells out an interesting future for Type 2 diabetes care – and market dynamics in that space. To ...